VIRI

Virios Therapeutics, Inc. [VIRI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VIRI Stock Summary

In the News

VIRI Financial details

Company Rating
-
Market Cap
9.87M
Income
-5.26M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
29 Feb 2024
P/E
-2.15
Forward P/E
-
PEG
0.29
P/S
-
P/B
2.78
P/C
-
P/FCF
-2.2
Quick Ratio
9.82
Current Ratio
10.77
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.28
EPS next Y
-
EPS next Q
-
EPS this Y
-74.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-11.44%
-
-
-
-
SMA20
10.02%
SMA50
-16.36%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-118%
ROE
-109%
ROC
-1.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.279-2.42
52W High
-
52W Low
-
RSI
51.44
Rel Volume
0.06
Avg Volume
386.86K
Volume
22.4K
Perf Week
-6.53%
Perf Month
-8.64%
Perf Quarter
-
Perf Half Y
-21.28%
-
-
-
-
Beta
1.881
-
-
Volatility
0.28%, 0.48%
Prev Close
1.6%
Price
4.44
Change
3.26%

Something similar

Top by Market Cap
CMC.DE
AVGO
BRK-B
LLY
AMZN
Same Sector
DCTH
PRPO
AXNX
INDRAMEDCO.NS
PAVM
Check Those
NXC
QWLD
1632.HK
000612.SZ
001872.SZ
Similar Market Cap
LCFE.L
CPP.L
CHLL.L
RORO
AWX

Company Profile

Healthcare Biotechnology
  • Volume Average 386.86K
  • Market Capitalization 9.87M
  • Employee 4
  • CEO Mr. Gregory Duncan
  • Headquarters Alpharetta,GA,US
  • IPO Date 2020-12-17
  • Website https://www.virios.com

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.